Meet
Haley Payne

She/Her
Consultant II

Haley Payne provides subject matter expertise in vaccines, preventive services, pandemic preparedness and response, and healthcare quality to support clients' above-brand and brand-level policy objectives.

She leverages experience in stakeholder engagement, advocacy, and state and federal health policy to help clients understand how they may engage with an evolving policy landscape, take advantage of opportunities, and anticipate potential barriers.

Prior to joining Avalere, Haley was the public health policy manager at the Infectious Diseases Society of America (IDSA), where she implemented the society’s policy activities around COVID-19, including vaccine authorization and distribution, and coordinated policy activities to combat antibiotic resistance and emerging infectious diseases. Previously, she served as a legislative associate at the Health and Medicine Counsel, where she represented a variety of patient and provider organizations on Capitol Hill.

Haley has an MPH from George Washington University and a BA in political science from Indiana University.

Authored Content


In this eBook, Avalere experts discuss the evolving vaccines ecosystem and analyze key policy issues affecting vaccines manufacturers.

Following policy changes addressing vaccine coverage gaps, stakeholders are focusing on provider financial and administrative barriers to vaccination.

The IRA expanded vaccine access, but variations in federal policies governing vaccine coverage requirements and implementation remain

In light of the growing therapeutic vaccine pipeline, policymakers are starting to define coverage, access, and reimbursement pathways.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

CMS is proposing to update vaccine administration reimbursement rates annually and make changes to adult vaccination quality metrics, beginning in 2023.

The rollout of COVID-19 vaccines highlights the need for continued innovation in how vaccines are delivered.

The COVID-19 pandemic identified gaps in US public health infrastructure and resources, prompting policy proposals and opportunities for stakeholder engagement.

Updated Avalere analysis shows that routine immunization continued to lag in 2021 below pre-pandemic levels, highlighting the continuing effect of COVID-19 on routine vaccination.

The COVID-19 pandemic has brought renewed attention and urgency to mitigating access barriers to recommended vaccines.

The COVID-19 pandemic response has increased investment in vaccine innovations, but also exposed gaps in US and global vaccine access and delivery.

As the COVID-19 pandemic draws to a close in the US, another public health concern is once again coming to the fore: antimicrobial resistance (AMR).